Department of Stomatology and Maxillofacial Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan.
Ann Nucl Med. 2010 Feb;24(2):77-82. doi: 10.1007/s12149-009-0326-5.
Clinical application of FDG-PET in head and neck cancer includes identification of metastases, unknown primary head and neck malignancy, or second primary carcinoma, and also recurrent tumor after treatment. In this study, the additional value of PET/CT fusion images over PET images alone was evaluated in patients with initial staging and follow up of head and neck malignancy.
Forty patients with suspected primary head and neck malignancy and 129 patients with suspected relapse after treatment of head and neck malignancy were included. FDG-PET/CT study was performed after the intravenous administration of FDG (5 MBq/kg). Target of evaluation was set at primary tumor, cervical lymph node, and whole body. PET images and PET with CT fusion images were compared. Sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) were calculated. Results of PET and PET/CT were compared with postoperative histopathological examination, and case by case comparison of PET and PET/CT results for each region was performed. The additional value of CT images over PET only images was assessed. Statistical differences in sensitivity and specificity were evaluated.
In the comparative evaluation of 507 targets by PET alone and PET/CT, 401 targets showed agreement of the results. Of the 106 discordant targets, 103 showed a positive result on PET alone and negative result on PET/CT. These results showed a significant difference (p< 0.01). Sensitivity of PET/CT was slightly higher than that of PET without statistical significance, while specificity of PET/CT was significantly higher than that of PET alone (Initial staging: 90.5% vs. 62.2%, p < 0.01; Follow up: 97.2% vs. 74.4%, p < 0.01). In Fisher's direct probability test, a significant difference was noted in the sensitivity (Initial staging: 91.3% vs. 87.0%, p < 0.01; Follow up: 93.9% vs. 91.4%, p <0.01).
Combined PET/CT showed improved diagnostic performance than PET alone by decreasing the number of false positive findings in patients with initial staging and follow up of head and neck malignancy.
FDG-PET 在头颈部癌症中的临床应用包括转移灶的识别、头颈部恶性肿瘤的不明原发灶或第二原发癌,以及治疗后的复发性肿瘤。在本研究中,评估了 PET/CT 融合图像相对于单独 PET 图像在初始分期和头颈部恶性肿瘤随访患者中的附加价值。
纳入 40 例疑似头颈部恶性肿瘤患者和 129 例疑似头颈部恶性肿瘤治疗后复发患者。静脉注射 FDG(5MBq/kg)后行 FDG-PET/CT 检查。评估的靶标为原发肿瘤、颈部淋巴结和全身。比较 PET 图像和 PET 与 CT 融合图像。计算灵敏度、特异性、准确性、阳性预测值(PPV)和阴性预测值(NPV)。将 PET 和 PET/CT 的结果与术后组织病理学检查进行比较,并对每个区域的 PET 和 PET/CT 结果进行逐一比较。评估 CT 图像相对于单纯 PET 图像的附加价值。评估灵敏度和特异性的统计学差异。
在单独 PET 和 PET/CT 对 507 个靶标的比较评估中,有 401 个靶标结果一致。在 106 个不一致的靶标中,103 个在单独 PET 上呈阳性结果,在 PET/CT 上呈阴性结果,差异有统计学意义(p<0.01)。PET/CT 的灵敏度略高于 PET,但无统计学意义,而 PET/CT 的特异性明显高于单独 PET(初始分期:90.5%比 62.2%,p<0.01;随访:97.2%比 74.4%,p<0.01)。在 Fisher 直接概率检验中,灵敏度差异有统计学意义(初始分期:91.3%比 87.0%,p<0.01;随访:93.9%比 91.4%,p<0.01)。
在头颈部恶性肿瘤的初始分期和随访中,与单独 PET 相比,PET/CT 可减少假阳性发现的数量,从而提高诊断性能。